SS-31 (also known as Elamipretide, Bendavia, or MTP-131) is a cell-permeable, mitochondria-targeted tetrapeptide that concentrates 1000-5000x in the inner mitochondrial membrane. Developed at the Szeto-Schiller lab at Weill Cornell, it was designed to target cardiolipin — a phospholipid critical for electron transport chain function.
Mitochondrial dysfunction is now recognized as a root cause of aging and age-related disease. As mitochondria deteriorate with age, electron transport becomes less efficient, ATP production drops, and reactive oxygen species (ROS) increase. SS-31 directly addresses this by restoring cardiolipin interactions with cytochrome c, normalizing electron transport and reducing ROS production.
SS-31 has been studied in clinical trials for heart failure, Barth syndrome, age-related macular degeneration, and primary mitochondrial myopathy. It represents one of the most scientifically rigorous approaches to targeting the mitochondrial basis of aging.